A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203
Launched by REPROS THERAPEUTICS INC. · Jun 30, 2011
Trial Information
Current as of June 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Successful completion of ZA-203
- • Ability to understand and provide written informed consent
- • Agreement to use a condom, and with a fertile female partner, another form of contraception
- • Agreement to provide semen samples in the clinic
- Exclusion Criteria:
- • Any condition which, in the opinion of the Investigator, would make the Subject an unsuitable candidate for enrollment in the study
About Repros Therapeutics Inc.
Repros Therapeutics Inc. is a biopharmaceutical company focused on the development of innovative therapies for unmet medical needs in women's health and men's health. The company specializes in the advancement of treatments for conditions such as hormonal disorders and reproductive health issues. By leveraging cutting-edge research and clinical expertise, Repros aims to deliver effective and safe therapeutic options that enhance the quality of life for patients. With a commitment to scientific excellence and patient-centered care, Repros Therapeutics is dedicated to driving forward the next generation of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Las Vegas, Nevada, United States
Houston, Texas, United States
San Diego, California, United States
Sacramento, California, United States
Garden Grove, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials